Full text

Turn on search term navigation

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Simple Summary

Nanopharmaceuticals have revolutionized the way ophthalmic drugs are administered to overcome ocular delivery barriers and improve drug bioavailability. The design and production of an efficient ocular drug delivery system still remain a challenge. In this review, we discuss the sterilization and depyrogenation methods, commonly used for ophthalmic nanopharmaceuticals, and their clinical applications.

Abstract

As an immune-privileged target organ, the eyes have important superficial and internal barriers, protecting them from physical and chemical damage from exogenous and/or endogenous origins that would cause injury to visual acuity or even vision loss. These anatomic, physiological and histologic barriers are thus a challenge for drug access and entry into the eye. Novel therapeutic concepts are highly desirable for eye treatment. The design of an efficient ocular drug delivery system still remains a challenge. Although nanotechnology may offer the ability to detect and treat eye diseases, successful treatment approaches are still in demand. The growing interest in nanopharmaceuticals offers the opportunity to improve ophthalmic treatments. Besides their size, which needs to be critically monitored, nanopharmaceuticals for ophthalmic applications have to be produced under sterilized conditions. In this work, we have revised the different sterilization and depyrogenation methods for ophthalmic nanopharmaceuticals with their merits and drawbacks. The paper also describes clinical sterilization of drugs and the outcomes of inappropriate practices, while recent applications of nanopharmaceuticals for ocular drug delivery are also addressed.

Details

Title
Nanopharmaceuticals for Eye Administration: Sterilization, Depyrogenation and Clinical Applications
Author
Zielińska, Aleksandra 1   VIAFID ORCID Logo  ; Soles, Beatriz B 2 ; Lopes, Ana R 2 ; Vaz, Beatriz F 2 ; Rodrigues, Camila M 2   VIAFID ORCID Logo  ; Alves, Thais F R 3 ; Klensporf-Pawlik, Dorota 4 ; Durazzo, Alessandra 5   VIAFID ORCID Logo  ; Lucarini, Massimo 5 ; Severino, Patricia 6   VIAFID ORCID Logo  ; Santini, Antonello 7   VIAFID ORCID Logo  ; Chaud, Marco V 3   VIAFID ORCID Logo  ; Souto, Eliana B 8 

 Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; [email protected] (A.Z.); [email protected] (B.B.S.); [email protected] (A.R.L.); [email protected] (B.F.V.); [email protected] (C.M.R.); Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland 
 Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; [email protected] (A.Z.); [email protected] (B.B.S.); [email protected] (A.R.L.); [email protected] (B.F.V.); [email protected] (C.M.R.) 
 Laboratory of Biomaterial and Nanotechnology (LaBNUS). University of Sorocaba, Raposo Tavares 92.5, Sorocaba, 18078-005 São Paulo, Brazil; [email protected] 
 Institute of Quality Science, Poznań University of Economics and Business, al. Niepodległości 10, 61-875 Poznań, Poland; [email protected] 
 CREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy; [email protected] (A.D.); [email protected] (M.L.) 
 Center for Biomedical Engineering, Department of Medicine, Brigham and Women& Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA; [email protected]; Biotechnological Postgraduate Program, University of Tiradentes (Unit), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil; Institute of Technology and Research (ITP), Nanomedicine and Nanotechnology Laboratory (LNMed), Av. Murilo Dantas, 300, 49010-390 Aracaju, Brazil; Tiradentes Institute, 150 Mt Vernon St, Dorchester, MA 02125, USA 
 Department of Pharmacy, University of Napoli Federico II, 80131 Napoli, Italy 
 Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; [email protected] (A.Z.); [email protected] (B.B.S.); [email protected] (A.R.L.); [email protected] (B.F.V.); [email protected] (C.M.R.); CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal 
First page
336
Publication year
2020
Publication date
2020
Publisher
MDPI AG
e-ISSN
20797737
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2546942900
Copyright
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.